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Abstract
The purpose of this study was to determine the relationship between total antioxidant capacity 
(TAC) from diet and supplements and prostate cancer aggressiveness among 855 African 
Americans (AA) and 945 European Americans (EA) in the North Carolina-Louisiana Prostate 
Cancer Project (PCaP). Cases were classified as either high aggressive, low aggressive, or 
intermediate aggressive. TAC was calculated from the vitamin C equivalent antioxidant capacity of 
42 antioxidants measured via food frequency questionnaire. EA reported greater dietary TAC from 
diet and supplements combined (P < 0.0001). In both minimally and fully adjusted logistic 
regression models, TAC from diet and supplements combined was associated with a reduced odds 
of high aggressive prostate cancer in all men, AA and EA: ORs for highest vs. lowest level (> 
1500 vs. < 500 mg VCE/d): 0.31 (95% CI: 0.15, 0.67; P-trend < 0.01), 0.28 (95% CI: 0.08, 0.96; 
P-trend < 0.001), and 0.36 (95% CI: 0.15, 0.86; P-trend = 0.58), respectively. These associations 
did not appear to differ between AA and EA. These data suggest that greater intake of antioxidants 
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is associated with less aggressive prostate cancer. Additional research is needed to confirm these 
results and determine the underlying mechanisms.
Introduction
Prostate cancer is the most common non-cutaneous cancer and second most common cause 
of cancer related mortality in men in the US, with an estimated 238,590 new cases and 
29,720 deaths in 2013 (1). The specific causes of prostate cancer have not yet been 
determined, but several risk factors have been identified for the disease, namely family 
history, age, and race (2, 3). There is also evidence that components of the diet, such as 
antioxidants found in the diet and supplements, also may be associated with prostate cancer 
risk. Men with prostate cancer have lower blood levels of vitamins E and C compared with 
controls (4), lower glutathione peroxidase and superoxide dismutase activity, and greater 
levels of malondialdehyde in erythrocytes (5, 6), all of which may reflect greater oxidative 
stress. Levels of antioxidants in the blood may interact with genetic variants for enzymes 
involved in inflammation (7) and DNA damage repair (8, 9). Based on this, as well as 
evidence from numerous human studies (10, 11), it is plausible that antioxidants from diet 
and supplements, such as vitamin E or carotenoids, may influence prostate cancer 
development and progression. Despite a large body of evidence for race and a growing body 
of evidence for diet as risk factors for prostate cancer relatively few studies have studied 
dietary antioxidants and prostate cancer in both African Americans (AA) and European 
Americans (EA) (12–14), two groups that exhibit a striking disparity in prostate cancer 
incidence and mortality (15).
However, studying the antioxidants present in diet and supplements is complicated by the 
sheer variety and magnitude of compounds that might affect prostate cancer. To examine the 
association between each individual antioxidant and prostate cancer risk would be 
impractical and likely to produce potentially spurious findings. One method for measuring 
dietary antioxidants that may circumvent such issues of multiplicity is the total antioxidant 
capacity (TAC) of the diet (16). TAC is a cumulative index of antioxidant intake. Greater 
dietary TAC has been associated with lower plasma concentrations of high-sensitivity C-
reactive protein (17) and a reduced risk of all-cause mortality (18). There has been one study 
of dietary TAC and prostate cancer to date (19), but there have been no reported studies of 
the association between dietary antioxidants and prostate cancer aggressiveness separately in 
European and African Americans. And while advanced or lethal prostate cancer is relatively 
rare, these forms of the disease have a greater risk of mortality and are arguably more 
clinically relevant than indolent forms of the disease (20). This demonstrates a need to 
determine whether antioxidant intake might influence risk of and racial disparities in 
aggressive forms of the disease, an important step in identifying modifiable lifestyle factors 
in an effort to reduce prostate cancer severity and mortality.
Thus, the purpose of the current study was to determine the association between dietary TAC 
and prostate cancer aggressiveness using data from a population-based study of prostate 
cancer aggressiveness among similar numbers of AA and EA. We hypothesized that dietary 
TAC would be inversely associated with prostate cancer aggressiveness.
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Methods
Data were analyzed from the North Carolina-Louisiana Prostate Cancer Project (PCaP), a 
population-based study of incident prostate cancer in AA and EA. Details of the study 
methods have been published (21). Research subjects were recruited from September 1, 
2004 to April 31, 2009, from 42 counties in North Carolina and 21 parishes in Louisiana. 
Men between 40 and 79 years of age with a first diagnosis of histologically confirmed 
adenocarcinoma of the prostate on or after July 1, 2004 were eligible to participate in PCaP. 
Men were not eligible to participate in the study if they were unable to complete the 
interview in English, living in an institution or nursing home, cognitively impaired, under 
the influence of alcohol, severely medicated, or apparently psychotic. Research subjects also 
must have self-identified as at least part AA or Black, or Caucasian or White (EA) when 
they responded to the open-ended question “What is your race?” The project was approved 
by the institutional review boards at the University of North Carolina, Louisiana State 
University Health Sciences Center, and the Department of Defense Prostate Cancer Research 
Program. The current study was approved by the Institutional Review Board at the 
University of Connecticut. Informed consent was obtained from all individual participants 
included in the study.
Data were collected by a series of structured questionnaires administered by PCaP nurses. 
Dietary data for the year prior to diagnosis were collected using the National Cancer 
Institute Diet History Questionnaire (NCI DHQ) (22), which was modified to include several 
Southern foods (e.g. grits, watermelon, and okra). Values for the flavonoid and 
proanthocyanidin content of foods were added to the DHQ database using Nutrition Data 
System for Research, version 2011 (Nutrition Coordinating Center, University of Minnesota, 
Minneapolis, MN). Antioxidants from supplements (both multivitamin and individual) that 
were considered in analyses included β-carotene, lycopene, lutein, α-tocopherol, and vitamin 
C; since dietary data was only available on lutein and zeaxanthin combined, lutein from 
supplements was added to dietary lutein and zeaxanthin to determine the combined amount 
of dietary and supplemental lutein and zeaxanthin. Total antioxidant capacity (TAC) was 
calculated from the vitamin C equivalent antioxidant capacity of 42 antioxidants 
(carotenoids, vitamins C and E, flavonoids, isoflavones, and proanthocyanidins) (Equation 
1). Vitamin C equivalent (VCE) antioxidant capacities of individual antioxidants were 
previously measured using the ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
radical anion scavenging activity assay using a vitamin C standard (23). Using this method, 
daily intake of these 42 antioxidants was converted to vitamin C equivalents and summed to 
yield an estimate of average TAC per day.
Equation 1
Calculation of theoretical TAC from diet and supplements, where D and S represent 
individual antioxidants from diet and supplements, respectively, in milligrams and C 
represents the vitamin C equivalent (VCE) antioxidant capacity per milligram of 
antioxidant.
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Clinical stage, Gleason score, and prostate-specific antigen (PSA) at diagnosis were 
obtained from medical record abstraction. Research subjects were classified as either high 
aggressive (Gleason sum ≥8, or PSA >20 ng/ml, or Gleason sum = 7 and clinical stage T3–
T4), low aggressive (Gleason sum <7 and clinical stage T1–T2 and PSA <10 ng/ml), or 
intermediate aggressive (all other cases). Results from PCaP using this categorization 
scheme have been published (24, 25), and are based on the risk strata described by the 
American Urological Association (26). A total of 2,258 men participated in PCaP. After 
excluding research subjects who did not respond to 5 or more questions on the DHQ (n=18), 
reported extreme or unlikely dietary TAC (defined as greater than 1.5 times the interquartile 
range of TAC from diet and supplements) (n=144), or were missing aggressiveness 
classification or data on covariates (n=292), 1,800 research subjects were included in all 
analyses.
Dietary TAC was adjusted for total energy intake using the residual method (27) and energy 
adjusted values for TAC were used in all analyses. Research subjects were divided into four 
categories based on TAC both from diet and from diet and supplements combined: < 500, 
500 ≤ 1000, 1000 ≤ 1500, and > 1500 mg VCE/d. These categories were determined based 
on visual assessment of a locally weighted scatter plot smoothing of TAC predicting 
aggressiveness (Figure 1). The relationship between TAC and prostate cancer aggressiveness 
was also determined by including TAC as a continuous predictor with the odds ratio 
reflecting a 500-unit increase in TAC. All statistical analyses were conducted using SAS 
software, version 9.3 (SAS Institute Inc., Cary, NC, USA). Chi-squared tests and Mann-
Whitney-Wilcoxon tests were used to test for significant differences between AA and EA.
Logistic regression was used to compare high to low and intermediate aggressive prostate 
cancer cases by categories of TAC from both diet alone and from diet and supplements, with 
a TAC of < 500 mg VCE/d as the referent category. Since the relationship between 
antioxidant intake and high aggressive prostate cancer was of interest, low and intermediate 
aggressive cases were collapsed into a single category. Interactions between aggressiveness, 
TAC, other covariates, and race were determined based on the significance of the interaction 
term and assessment using 3-way tables; since a significant interaction was found between 
smoking status, race, and aggressiveness, an interaction term between smoking and race was 
included in logistic regression models. Logistic regression model 1 was adjusted for age, 
race, smoking status, and race-smoking interaction. Model 2 consisted of model 1, 
additionally adjusted for poverty index, marriage, previous digital rectal examination (DRE) 
and prostate specific antigen (PSA) screening, and body mass index. These control variables 
were chosen since they are likely to be associated with both antioxidant intake and prostate 
cancer. An interaction term between race and TAC was included in all models to allow for 
the calculation of odds ratios for all men, AA, and EA from each model. Linear contrasts 
were used to test for the significance of a linear trend in the odds ratios for each group. All 
P-values reported are two sided (α = 0.05). To visualize the relationship between TAC and 
prostate cancer aggressiveness for all men, and AA and EA separately, the odds ratios and 
95% confidence intervals were plotted for TAC predicting prostate cancer aggressiveness in 
fully adjusted models as a linear predictor and as a restricted cubic spline with knots located 
at the 10th, 50th, and 90th percentiles (Figure 2 and 3).
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Results
Prostate cancer cases included 459 AA and 498 EA from Louisiana and 396 AA and 447 EA 
from North Carolina (Table 1). Since site was not a significant predictor (P = 0.99) it was 
excluded from all regression models. There were no significant differences between subjects 
included and excluded from analyses for variables in Table 1 (data not shown). Compared to 
EA, more AA had high aggressive prostate cancer, no previous PSA or DRE test, no health 
insurance, and were classified as borderline or below poverty thresholds by the US Census 
Bureau (P < 0.05). A greater proportion of EA were classified as overweight or obese, 
married, nonsmokers, and reported attaining college or professional education (P < 0.05). 
Compared with AA, EA consumed more antioxidants from supplements and from diet and 
supplements combined (Table 2).
The results of logistic regression models of the association between TAC and odds of high 
aggressive prostate cancer are reported in Table 3. There were no statistically significant 
interactions between TAC and race (data not shown), which indicates that there is no 
evidence that the association between TAC and prostate cancer aggressiveness differed 
between AA and EA. In Model 1, there was evidence of a reduced odds of high aggressive 
prostate cancer in all men (P-trend < 0.05) with greater dietary TAC. This trend remained in 
Model 2 after adjusting for additional covariates (P-trend < 0.01). When stratified by race, a 
decreasing trend in the odds of high aggressive cancer was more evident among AA (Model 
2, P-trend < 0.01). Among EA, greater dietary TAC was associated with a reduced odds of 
high aggressive prostate cancer, and most apparent among men reporting the greatest dietary 
TAC, OR 0.22 (95% CI: 0.05, 0.97). These results were consistent with those of dietary TAC 
modeled as a continuous variable (Figure 2), with a 500-unit increase in dietary TAC 
corresponding to odds ratios of 0.81 (95% CI: 0.67, 0.97) for all men, 0.81 (95% CI: 0.62, 
1.07) for AA, and 0.80 (95% CI: 0.62, 1.03) for EA in analyses adjusted for all covariates 
(Table 3).
Greater TAC from both diet and supplements was associated with a significant reduction in 
odds of high aggressive prostate cancer among all men and AA in the fully adjusted Model, 
with greatest vs. lowest TAC ORs 0.31 (95% CI: 0.15, 0.67; P-trend < 0.01) and 0.28 (95% 
CI: 0.08, 0.96; P-trend < 0.001), respectively. For EA, men reporting the greatest TAC from 
diet and supplements had a significantly reduced odds of high aggressive prostate cancer, 
OR 0.36 (95% CI: 0.15, 0.86). These results are similar to those when TAC of diet and 
supplements was modeled as a continuous variable (Figure 3), though a dose response in the 
OR was more apparent for EA than for categorical analyses. In analyses adjusted for all 
covariates, a 500-unit increase in TAC from diet and supplements corresponded to an odds 
ratio of 0.84 (95% CI: 0.72, 0.98) for all men, 0.83 (95% CI: 0.65, 1.06) for AA, and 0.84 
(95% CI: 0.68, 1.04) for EA (Table 3).
Discussion
Men with prostate cancer have been found to have low blood levels of dietary antioxidants 
(4), decreased activity of endogenous antioxidant enzymes, and increased levels of lipid 
peroxidation (5, 6). These findings could indicate either greater oxidative stress resulting in 
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depletion of antioxidants or lower levels of antioxidants resulting in increased oxidative 
stress and lipid peroxidation. Furthermore, levels of antioxidants in the blood may interact 
with genetic variants for cyclooxygenase-2 and interleukin-8, which are involved in 
inflammatory processes (7), and human oxoguanine glycosylase 1 and X-ray repair cross-
complementing group 1, which are involved in repairing DNA damage (8, 9). Thus, it is 
plausible that dietary antioxidants may influence prostate cancer development and 
progression by compensating for imbalances in oxidative stress.
In this study, dietary TAC was associated with a reduced odds of high aggressive prostate 
cancer. In logistic regression models, TAC from both diet alone and diet and supplements 
was associated with reduced odds of high aggressive prostate cancer among all men. We 
found no evidence that this association differed by race, with TAC from all sources 
associated with reduced odds of high aggressive prostate cancer among all men (Table 3 and 
Figures 2 and 3).
While there is evidence that antioxidants in the diet may influence risk of prostate cancer, 
previous studies have yielded conflicting results. Several antioxidants from both diet and 
supplements have been associated with prostate cancer risk (10, 28). For example, increased 
intake of vitamin E as supplemental α-tocopherol has been associated with a reduced risk of 
prostate cancer in the α-tocopherol, β-carotene Cancer Prevention Study (ATBC) (29), but 
also has been associated with an increased risk of prostate cancer in SELECT, the Selenium 
and Vitamin E Cancer Prevention Trial (30). Several other studies have found no effect of 
vitamin E on prostate cancer risk (31–33). However, Wright et al (34) found a significant 
association between increased dietary γ-tocopherol and decreased risk of prostate cancer. A 
similar finding was observed in the ATBC study (35). γ-Tocopherol has been shown to 
promote apoptosis (36) and inhibit growth (37) in prostate cancer cell lines. Similarly with 
vitamin E, studies on β-carotene have reported inverse (38–40) or positive (29) associations, 
and null associations with β-carotene or other carotenoids (41–46). And β-cryptoxanthin has 
been shown to be positively (47, 48), negatively (49), or not associated (50) with risk of 
prostate cancer. Previous studies on vitamin C and prostate cancer have observed no effect 
(31, 32, 41, 43, 47, 51, 52). There is limited evidence regarding dietary flavonoids, but in an 
Italian case-control study flavonoids were not associated with risk of prostate cancer (53). 
While an index of overall antioxidant intake, such as TAC, may serve as an alternative to 
measuring individual dietary antioxidants, the evidence to date suggests that the biological 
role of antioxidants in prostate cancer is unclear, with the benefits and harms of some 
antioxidants more apparent than others.
The results from studies using blood biomarkers of dietary antioxidants further demonstrates 
this variability. In a nested case-control study from SELECT, plasma α-tocopherol was 
positively associated with prostate cancer incidence, but no association was evident for γ-
tocopherol (54). A nested case-control study from the Prostate, Lung, Colorectal and 
Ovarian (PLCO) Cancer Screening Trial found evidence of a possible association between 
serum γ-tocopherol and increased risk of prostate cancer (55). In another nested case-
control-study of the PLCO cancer screening trial, serum β-carotene was positively associated 
with risk of aggressive prostate cancer, and there appears to be little evidence serum 
concentrations of other carotenoids (56). One exception is lycopene, where most of the 
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evidence for a protective effect in some subgroups of men comes from the Health 
Professionals’ Follow-up Study (57). However, in general the data on associations between 
prostate cancer risk and blood biomarkers of antioxidant intake is unclear (56). This may be 
partly attributable to confounding by genetic variation affecting blood levels of carotenoids 
(58) and tocopherols (59), in which case future research should shed more light on the 
subtleties in the biological mechanisms of dietary components and their influence on disease 
risk.
While men with prostate cancer have been found to have significantly lower serum TAC 
(60), there is relatively little evidence on the association between dietary antioxidant 
capacity and its association with prostate cancer. To the author’s knowledge this is the first 
study of prostate cancer aggressiveness and TAC in both AA and EA. A recent publication 
by Russnes et al. (61) found no association between prostate cancer incidence and TAC from 
diet and supplements combined, although when considered separately there was a weak 
negative association with TAC from diet and prostate cancer incidence and a weak positive 
association with TAC from supplements for lethal and advanced prostate cancer. In the 
current study a reduced odds of high aggressive prostate cancer was observed with greater 
TAC from diet and supplements. One reason for this difference may be that Russnes et al. 
examined the association between TAC on prostate cancer incidence, whereas in the present, 
cross-sectional study the temporality of associations cannot be certain. Another reason may 
be the method used to determine TAC; the present study used the ABTS assay, which 
measures the radical scavenging potential of antioxidants, whereas Russnes et al. used the 
ferric-reducing antioxidant power (FRAP) assay, which measures the reducing power of 
antioxidants; thus, these two measures may not be directly comparable (62) and it has been 
argued that FRAP does not actually reflect total antioxidant capacity (63).
Furthermore, in this study TAC was estimated indirectly using the vitamin C equivalent 
antioxidant capacity of individual antioxidants, measured using the ABTS assay. Unlike 
most studies of TAC, in which TAC has been calculated based on oxygen radical absorbance 
capacity (ORAC) or FRAP databases, our research group developed a new method to assess 
dietary TAC by summing the VCE antioxidant capacities of major individual antioxidants 
using the ABTS assay (64). This approach has been validated and applied in several studies 
(23, 65, 66), as it agrees well with the phenolic and flavonoid content and experimentally 
determined TAC of foods (23). While this method does not measure the antioxidant capacity 
of foods directly, it has several advantages. It can be applied to any food composition data 
for which information on individual antioxidants is available, and the units, vitamin C 
equivalents, are more easily understood and comparable with Trolox equivalents used in 
other measures of TAC (67). However, a limitation of measuring TAC indirectly is that there 
are likely many antioxidants present in foods that are not accounted for in current food 
composition tables, and thus it is possible that this method may not precisely reflect the 
actual TAC of foods. This is especially the case for proanthocyanidins and flavonoids, data 
for which are sparse or lacking in most food composition databases. Russnes et al. measured 
the FRAP of individual foods directly, and thus it is plausible that measurements from this 
method in part reflect food components that have limited or no bioavailability. Thus, each 
method of measuring TAC is based on certain assumptions and has different strengths and 
limitations that should be considered.
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This study had several strengths. Rapid case ascertainment used in PCaP limited the time 
between diagnosis and enrollment, thus reducing the likelihood of bias from time or 
treatment. PCaP was designed to accurately capture information on prostate cancer 
aggressiveness at diagnosis among an ethnically and geographically diverse population, 
while most studies have examined risk of developing prostate cancer. Furthermore, the use 
of less aggressive cases as controls allowed for the identification of factors associated with 
aggressive prostate cancer at diagnosis rather than risk of developing the disease.
Limitations of this study include a case-only design. All data were collected after diagnosis, 
thus treatment or disease may have biased the responses of research subjects. The time and 
reason for an initial diagnosis of prostate cancer also may have introduced bias. The measure 
of prostate cancer aggressiveness used may not reliably indicate future disease progression, 
particularly since participants were recruited during the PSA screening era. Dietary data 
were collected by a modified NCI DHQ that included Southern foods and this modified food 
frequency questionnaire has not been validated. However, the unmodified DHQ to which 
these changes were made has been previously validated (68) and while it is possible that 
these changes affected the validity of the DHQ, it seems unlikely that these changes would 
have introduced differential bias. Furthermore, antioxidant intake from supplements may be 
underestimated, as data on antioxidants in supplements were limited to vitamin C, α-
tocopherol, β-carotene, lycopene, and lutein (e.g. the effects of selenium were not 
examined). Since the number of men in the upper categories of intake is very small these 
results should be interpreted cautiously. Since this study was cross-sectional, whether dietary 
antioxidants have an effect on the pathological progression of prostate cancer cannot be 
determined; however, these results warrant further research.
In conclusion, dietary and supplemental TAC was found to be inversely associated with odds 
of high aggressive prostate cancer in AA and EA. This study does not provide evidence that 
dietary antioxidants are associated with prostate cancer aggressiveness differently in AA and 
EA. However, further studies in other populations are required to confirm these results and 
determine whether dietary components effect the development and progression of prostate 
cancer.
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Figure 1. 
LOESS plot of average daily TAC from diet and supplements predicting prostate cancer 
aggressiveness. The solid line is the smoothed LOESS line of TAC predicting 
aggressiveness; empty circles represent individual participants. The smoothing parameter 
was chosen based on minimization of the corrected Akaike information criterion (AICC). 
Abbreviations: TAC, total antioxidant capacity; VCE, vitamin C equivalents.
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Figure 2. 
Plot of odds ratio (black) and 95% confidence interval (grey) for total antioxidant capacity 
(TAC) of diet predicting odds of prostate cancer aggressiveness for all men, African 
Americans, and Caucasian Americans. Solid lines represent linear model of TAC on a 
continuous scale; broken lines represent model of TAC using a restricted cubic spline with 
knots located at the 10th, 50th, and 90th percentiles. Models adjusted for average energy 
intake, age, smoking, race, race-smoking interaction, poverty index, marriage, body mass 
index, and DRE and PSA screening. Results by race determined using an interaction term 
between TAC and race.
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Figure 3. 
Plot of odds ratio (black) and 95% confidence interval (grey) for total antioxidant capacity 
(TAC) of diet and supplements predicting odds of prostate cancer aggressiveness for all men, 
African Americans, and Caucasian Americans. Solid lines represent linear model of TAC on 
a continuous scale; broken lines represent model of TAC using a restricted cubic spline with 
knots located at the 10th, 50th, and 90th percentiles. Models adjusted for average energy 
intake, age, smoking, race, race-smoking interaction, poverty index, marriage, body mass 
index, and DRE and PSA screening. Results by race determined using an interaction term 
between TAC and race.
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